This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
1403-0001
Phase 1 other active
Quick answer
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) for Advanced or metastatic solid tumors is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Advanced or metastatic solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active